Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: A US claims database study

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Bergvall, Niklas ^a   Makin, Charles ^b   Lahoz, Raquel ^a   Agashivala, Neetu ^a   Pradhan, Ashish ^a   Capkun, Gorana ^a   Petrilla, Allison A ^b   Karkare, Swapna U ^b   McGuiness, Catherine Balderston ^b   Korn, Jonathan R ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; GLATIRAMER; INTERFERON; PEPTIDE; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ALGORITHM; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PATIENT SELECTION; PROBABILITY; PROPENSITY SCORE; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; DEMOGRAPHY; FACTUAL DATABASE; FEMALE; INSURANCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE; TIME; UNITED STATES;

COHORT STUDIES; DATABASES, FACTUAL; DEMOGRAPHY; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; INTERFERONS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROPYLENE GLYCOLS; RECURRENCE; SPHINGOSINE; TIME FACTORS; UNITED STATES;

EID: 84895552294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088472     Document Type: Article

References (49)

1. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359: 1221-1231. (Pubitemid 34304266)
2. Rolak LA (2003) Multiple sclerosis: it's not the disease you thought it was. Clin Med Res 1: 57-60.
3. Zwibel HL, Smrtka J (2011) Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care 17 Suppl 5 Improving: S139-145.
4. Bainbridge JL, Rieckmann P, editors (2008) Multiple sclerosis. In: DiPiro JT, Talbert R, Yee G, Matzke G, editors. Pharmacotherapy: a pathophysiologic approach. : New York: McGraw-Hill Medical. 913-926 p.
5. Lublin FD, Baier M, Cutter G (2003) Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61: 1528-1532. (Pubitemid 37505574)
6. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, et al. (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112 (Pt 6): 1419-1428. (Pubitemid 20024212)
7. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-911.
8. IFNB study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661.
9. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285-294. (Pubitemid 26100751)
10. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, et al. (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 6: 255-266.
11. Freedman SM (2009) Dose response to interferon therapy in multiple sclerosis: an evaluation of the evidence. Curr Med Res Opin 25: 547-557.
12. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, et al. (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7: 903-914.
13. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, et al. (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8: 889-897.
14. Derwenskus J (2011) Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 78: 161-175.
15. Reynolds MW, Stephen R, Seaman C, Rajagopalan K (2010) Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ 13: 90-98.
16. Margolis JM, Fowler R, Johnson BH, Kassed CA, Kahler K (2011) Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol 11: 122.
17. Stavnitser A, Patel NV, Miller AR, Matlin OS (2013) Impact of new oral therapies on multiple sclerosis cost and utilization trends. AJMP.com. Available: http://www.ajmc.com/publications/ajpb/2013/ajpb-janfeb2013/impact-of- new-oral-therapies-on-multiple-sclerosis-cost-and-utilization-trends/2#sthash. ugsLgk21.dpuf. Accessed 22 July 2013.
18. Fernandez O, Fernandez V, Mayorga C, Guerrero M, Leon A, et al. (2005) HLA class II and response to interferon-beta in multiple sclerosis. Acta Neurol Scand 112: 391-394. (Pubitemid 41695719)
19. Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, et al. (2011) Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 77: 1684-1690.
20. Giovannoni G, Southam E, Waubant E (2012) Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 18: 932-946.
21. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA (2010) Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 30: 89-100.
22. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S (2011) Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 28: 51-61.
23. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
24. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, et al. (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 10: 520-529.
25. Collins W, Cohen J, O'Connor P, de Vera A, Zhang-Auberson L, et al. (2010) Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies. Mult Scler 16: S295.
26. Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA (2012) Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci 15: 167-172.
27. Edwards KR, Crayton H, Calkwood J, Agashivala N, Li S, et al. (2013) Patient-and physician-reported outcomes after therapy switch from interferon beta to fingolimod vs staying on interferon beta therapies. ECTRIMS 29th Congress of the European Committee, October 2-5 2013. Available: http://registration.akm.ch/einsicht.php?XNABSTRACT-ID = 180055&XNSPRACHE-ID = 2&XNKONGRESS-ID = 195&XNMASKEN-ID = 900. Accessed 16 January 2014.
28. Cree B, Kantor D, Steingo BM, Agashivala N, Li S, et al. (2013) Patient- and physician-reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. ECTRIMS 29th Congress of the European Committee, October 2-5 2013. Available: http://registration.akm.ch/ einsicht.php?XNABSTRACT-ID = 180010&XNSPRACHE-ID = 2&XNKONGRESS-ID = 195&XNMASKEN-ID = 900. Accessed 16 January 2014.
29. Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, et al. (2013) Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol 13: 138.
30. Fox E, Edwards K, Burch JG, Kim E, Pestreich L, et al. (2013) Treatment satisfaction and clinical improvement after switch to fingolimod. Poster presented at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, May 29-Jun 1, 2013, Orlando, FL. Available at: https://cmscactrims. confex.com/cmscactrims/2013/webprogram/Paper1203.html. Accessed 22 June 2013.
31. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61: 344-349. (Pubitemid 351289042)
32. Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46: 399-424.
33. D'Hoore W, Sicotte C, Tilquin C (1993) Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 32: 382-387. (Pubitemid 24001924)
34. Roos LL, Stranc L, James RC, Li J (1997) Complications, comorbidities, and mortality: improving classification and prediction. Health Serv Res 32: 229-238; discussion 239-242.
35. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV (2010) Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 13: 618-625.
36. Ollendorf DA, Jilinskaia E, Oleen-Burkey M (2002) Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 8: 469-476.
37. Capkun-Niggli G, Lahoz R, Verdun E, Dickinson S, Lowy A, et al. (2013) Medical and pharmacy claims-based algorithms for identifying relapses in patients with multiple sclerosis. Value in Health 16: A582.
38. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M (2011) Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence 5: 73-84.
39. Caon C, Din M, Ching W, Tselis A, Lisak R, et al. (2006) Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 13: 471-474. (Pubitemid 43823361)
40. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317: 408-414. (Pubitemid 17131177)
41. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49: 290-297. (Pubitemid 32202781)
42. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: 1268-1276.
43. Ollendorf DA, Castelli-Haley J, Oleen-Burkey M (2008) Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis. J Neurosci Nurs 40: 281-290.
44. Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA (2012) Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Curr Med Res Opin 28: 767-780.
45. Goodin DS (2008) Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 71: S8-13.
46. Rich SR, Coleman IC, Cook R, Hum DS, Johnson B, et al. (2004) Stepped-care approach to treating MS: a managed care treatment algorithm. J Manag Care Pharm 10: S26-32.
47. Chin PS, Calabresi PA, Zhang Y, von Rosenstiel P, Kappos L (2012) Early effect of fingolimod on clinical and MRI related outcomes in relapsing multiple sclerosis. ECTRIMS 10-13 October 2012. Available: http://registration.akm. ch/einsicht.php?XNABSTRACT-ID = 156571&XNSPRACHE-ID = 2&XNKONGRESS-ID = 171&XNMASKEN-ID = 900. Accessed 16 January 2014.
48. Hartung HP (2013) Relationship between early disease activity and long-term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing-remitting multiple sclerosis. 23rd Meeting of the European Neurological Society 8-11. Availabe: http://www.multiwebcast.com/ens/ 2013/23rd/28284/prof.hans-peter.hartung.relationship.between.early.disease. activity.and.html. Accessed 16 January 2014; 2013 June 2013.
49. Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, et al. (2012) Comparison of time to discontinuation among multiple sclerosis patients receiving fingolimod and other first-line disease modifying treatment. ECTRIMS 28th Congress of the European Committee, October 10-13 2012. Available: http://registration. akm.ch/einsicht.php?XNABSTRACT-ID = 156370&XNSPRACHE-ID = 2&XNKONGRESS-ID = 171&XNMASKEN-ID = 900. Accessed 16 January 2014.